Bill Text: CA AB1963 | 2017-2018 | Regular Session | Introduced

NOTE: There are more recent revisions of this legislation. Read Latest Draft

---

Bill Title: Medi-Cal: reimbursement: opioid addiction treatment.

Spectrum: Slight Partisan Bill (Republican 2-1)

Status: (Introduced - Dead) 2018-05-25 - In committee: Held under submission. [AB1963 Detail]

Download: California-2017-AB1963-Introduced.html

---

CALIFORNIA LEGISLATURE— 2017–2018 REGULAR SESSION

Assembly Bill

No. 1963

---

Introduced by Assembly Member Waldron

January 30, 2018

---

An act to add Section 14105.197 to the Welfare and Institutions Code, relating to Medi-Cal.

LEGISLATIVE COUNSEL'S DIGEST

AB 1963, as introduced, Waldron. Medi-Cal: reimbursement: opioid addiction treatment.

Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law establishes the Drug Medi-Cal Treatment Program (Drug Medi-Cal), under which the department is authorized to enter into contracts with each county, or enter into contracts directly with certified providers, for the provision of various alcohol and drug use treatment services, including substance use disorder services, narcotic treatment program services, naltrexone services, and outpatient drug-free services, to Medi-Cal beneficiaries.

This bill would require the department to increase the Medi-Cal provider reimbursement rates, as specified, for buprenorphine/naloxone combination treatment, or similar treatment services, provided by certified providers, for opioid addiction.

Digest Key

Vote: MAJORITY   Appropriation: NO   Fiscal Committee: YES   Local Program: NO  

---

Bill Text

The people of the State of California do enact as follows:

SECTION 1.

 Section 14105.197 is added to the Welfare and Institutions Code, to read:

14105.197.

 The department shall increase the Medi-Cal provider reimbursement rates, by __ percent of the corresponding average rates established in the 2017–18 fiscal year, for buprenorphine/naloxone combination treatment, classified in Schedule III pursuant to the California Uniform Controlled Substances Act (Division 10 (commencing with Section 11000) of the Health and Safety Code), or similar treatment services, provided by certified providers, for opioid addiction.